Cognition Therapeutics, Inc.

Zervimesine Shows Promise in Dry AMD Treatment with Positive Phase 2 Data

3 months ago

• Cognition Therapeutics' oral drug candidate zervimesine (CT1812) demonstrates potential in treating dry AMD, with Phase 2 MAGNIFY trial data showing slower lesion growth rates compared to placebo. • Analysis of cerebrospinal fluid from Alzheimer's disease trials reveals zervimesine's ability to alter proteins and pathways associated with geographic atrophy and macular degeneration. • In vitro studies demonstrate zervimesine's capacity to normalize retinal pigment epithelial cell function when compromised by amyloid beta oligomers or oxidative stress.

Zervimesine Shows Promise in Geographic Atrophy Trial, Building on Success in Multiple CNS Disorders

3 months ago

• Cognition Therapeutics' Phase 2 MAGNIFY trial of zervimesine demonstrates slower lesion growth in geographic atrophy patients compared to placebo after 6 months of treatment. • The drug previously showed significant benefits in dementia with Lewy bodies trials, with patients showing 86% improvement in neuropsychiatric symptoms and 62% better motor function versus placebo. • Zervimesine also demonstrated strong results in Alzheimer's disease trials, achieving a 95% reduction in cognitive decline in a biomarker-defined subgroup compared to placebo.

Cognition Therapeutics Reveals Promising Biomarker Strategy for Alzheimer's Treatment Patient Selection

3 months ago

• Cognition Therapeutics' Phase 2 SHINE study demonstrates that Alzheimer's patients with lower p-tau217 levels showed 95% improvement on ADAS-Cog 11 and 108% better MMSE scores with zervimesine treatment versus placebo. • Dr. Mary Hamby, VP of Research at Cognition, will co-host a precision medicine workshop at the Neuroimmunology Drug Development Summit, focusing on optimizing patient selection for clinical trials. • The company's findings suggest plasma p-tau217 could serve as a simple blood-based biomarker to identify Alzheimer's patients most likely to benefit from beta amyloid-targeted therapies.

Cognition Therapeutics Develops Enhanced Manufacturing Process for Alzheimer's Drug Candidate Zervimesine

3 months ago

• Cognition Therapeutics has published a new chemical manufacturing process for zervimesine (CT1812), featuring improved room temperature stability and enhanced production efficiency through innovative technologies. • The company has filed provisional patent applications for both the manufacturing process and a novel polymorphic form of zervimesine, strengthening their intellectual property position. • Zervimesine, an oral daily treatment targeting toxic protein buildup in Alzheimer's and DLB, is currently undergoing clinical trials with potential to slow disease progression.

Cognition Therapeutics CEO to Present Alzheimer's and DLB Progress at Upcoming Conferences

4 months ago

• Cognition Therapeutics CEO Lisa Ricciardi will discuss progress in Alzheimer's and dementia with Lewy body (DLB) programs at upcoming conferences. • Positive topline results from the Phase 2 SHIMMER study in DLB patients will be presented at the International Lewy Body Dementia Conference. • Cognition is preparing for an end-of-Phase 2 meeting with the FDA to review results from the SHINE study in mild-to-moderate Alzheimer’s disease. • The generic name for Cognition's drug candidate CT1812 has been cleared and will be known as zervimesine.

Cognition Therapeutics' CT1812 Shows Promise in Phase 2 Trials for Alzheimer's and Lewy Body Dementia

7 months ago

• Cognition Therapeutics' CT1812 demonstrated a 95% slowing of cognitive decline in Alzheimer's patients with lower plasma p-tau217 levels in Phase 2 SHINE study. • The Phase 2 SHIMMER study of CT1812 in dementia with Lewy bodies (DLB) met its primary endpoint of safety and tolerability. • DLB patients treated with CT1812 showed an 82% slowing in neuropsychiatric symptoms and a 91% reduction in attention fluctuations. • Cognition Therapeutics plans to advance CT1812 into late-stage clinical trials and discuss Phase 3 trial design with the FDA.